Scancell featured in the Guardian Focus on the exciting potential of T-cell immunity is spurring the sector on to create a new generation of jabs The speed at which scientists worked to develop the first Covid jabs was unprecedented. Just nine months after the UK went into lockdown, 90-year-old Margaret Keenan officially became the first person in … Continued
Approval granted for clinical trial in South Africa Vaccine targets the core of the virus, not just the spike protein eliciting a t-cell response which can destroy cells infected with any SARS CoV-2 variants and other SARS-CoV viruses that may emerge in the future. Scancell, the developer of novel immunotherapies for the treatment of cancer … Continued
Scancell was featured in the Telegraph on Saturday 13 February. The Company are developing a universal vaccine that would work on all Covid-19 variants by targeting the core of the virus instead of just the spike protein. It could be available in as little as a year. Please find extract below – ‘British scientists at … Continued
Scancell has secured funding from Innovate UK, the UK’s Innovation Agency, through the ‘UK Research and Innovation (UKRI) Ideas to Address COVID-19’ funding strand The funding will be used to initiate a Phase 1 clinical trial (“COVIDITY”) during 2021. The project is being led by Professor Lindy Durrant, Chief Scientific Officer of Scancell and Professor … Continued
Scancell, the developer of novel immunotherapies for the treatment of cancer, has developed a technique where DNA is injected into patients to create T-cells that recognise and destroy cancer cells.